Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
about
Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesDetection, Assessment, and Management of Schizophrenia in an Andean Population of South America: Parkinsonism Testing and Transcranial Ultrasound as Preventive Tools.Extrapyramidal side-effects of antipsychotics in a randomised trial.Tardive dyskinesia: therapeutic options for an increasingly common disorder.BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysisCommunity care of patients with schizophrenia: the role of the primary health care teamIncidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.Tardive and spontaneous dyskinesia incidence in the general population.Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort studyEthical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone.Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.Hot tongue on FDG PET scan in a patient of Hodgkin's lymphoma undergoing antipsychotic treatment.Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia.Major complications of neuroleptic drug use.
P2860
Q28088705-D321A98C-E697-48ED-AA50-AEB3F7D09891Q30373174-20B7DBB5-2DE6-408D-B226-33F22C2E0D83Q30492645-2B967C7E-FCBE-483E-BC45-7582B549BD0FQ30566749-C57B822B-5B85-48DD-9C46-E20516B0E975Q33566832-D7FA3DB2-2B8C-41C3-87AF-5C99FD612233Q34054749-368F7C9D-6CBE-45AC-A561-803E50406EC8Q34628702-008D0778-9567-4E28-82B9-33040F0FF744Q34743134-D597B6A3-6ADC-43CE-A000-0C5429DC1524Q35030003-BF5CD957-9E49-4A39-BBAE-D8DDCAF7416CQ35693061-D1C53996-CD8A-41F5-9F46-A924F26D8111Q36965451-E9D5F741-DF50-40CD-9409-AE19B275682AQ37224571-FFEDCF40-A867-4795-8F6B-2235EE50DF7EQ37302639-A60ADA4C-E683-432A-ACEA-02A5C82D4ACAQ41195651-FD3D5ED7-42DD-4889-A86A-078CFA74E133Q42167074-12846886-7E57-4076-AA3D-D5092C61C90EQ42574318-819EDBB9-87D4-4117-8A3E-BAE3FAEC5A61
P2860
Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
description
1993 nî lūn-bûn
@nan
1993 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Predicting the long-term risk ...... ed on neuroleptic medications.
@ast
Predicting the long-term risk ...... ed on neuroleptic medications.
@en
Predicting the long-term risk ...... ed on neuroleptic medications.
@nl
type
label
Predicting the long-term risk ...... ed on neuroleptic medications.
@ast
Predicting the long-term risk ...... ed on neuroleptic medications.
@en
Predicting the long-term risk ...... ed on neuroleptic medications.
@nl
prefLabel
Predicting the long-term risk ...... ed on neuroleptic medications.
@ast
Predicting the long-term risk ...... ed on neuroleptic medications.
@en
Predicting the long-term risk ...... ed on neuroleptic medications.
@nl
P2093
P1476
Predicting the long-term risk ...... ned on neuroleptic medications
@en
P2093
Doucette JT
Morgenstern H
P304
P577
1993-04-01T00:00:00Z